The Food and Drug Administration (FDA) told the maker of Purell to discontinue marketing campaigns that includes claims for avoiding flu and ebola, according to an article on The New York Times website.
The campaigns also claim the product can prevent spread of MRSA and norovirus.
The FDA told Gojo Industries that its claims that Purell could reduce the potential for infection or prevent illnesses violated the Federal Food, Drug and Cosmetic Act.
The agency said it was reclassifying Purell as an unapproved drug, rather than an over-the-counter product.
Spaces That Support: Patient-Centered Design for Modern Reproductive Health
Modernization of Buildings Require Collaboration Across All Disciplines
Children's Health Announces Plans for RedBird Specialty Center in Texas
How Can Healthcare Facilities Use Efficiency to Drive Climate and Health Goals?
El Camino Health Rehabilitation Hospital Officially Tops Out